Crossject SA
PAR:ALCJ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Crossject SA
Total Equity
Crossject SA
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Crossject SA
PAR:ALCJ
|
Total Equity
€3.7m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-10%
|
|
|
Guerbet SA
PAR:GBT
|
Total Equity
€267m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-1%
|
|
|
Affluent Medical SAS
PAR:AFME
|
Total Equity
€30.3m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Crossject SA
Glance View
Crossject SA manufactures and markets needle-free injection system. The company is headquartered in Dijon, Bourgogne-Franche-Comte. The firm specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The firm's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject’s first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The firm has industrial partnerships with Hirtenberger and Recipharm.
See Also
What is Crossject SA's Total Equity?
Total Equity
3.7m
EUR
Based on the financial report for Jun 30, 2025, Crossject SA's Total Equity amounts to 3.7m EUR.
What is Crossject SA's Total Equity growth rate?
Total Equity CAGR 10Y
-10%
Over the last year, the Total Equity growth was 107%. The average annual Total Equity growth rates for Crossject SA have been -30% over the past three years , -17% over the past five years , and -10% over the past ten years .
